© Reuters. Senseonics vs. Insulet: Which Diabetes Stock is Better to Buy?
Senseonics Holdings (NYSE 🙂 and Insulet (NASDAQ 🙂 are two health stocks that have the potential to outperform broader markets over the long term. The two companies are part of a rapidly growing market that enables them to increase sales and improve bottom line. But which of the two diabetes stocks should you buy today? A research report by the World Health Organization estimates diabetes cases worldwide at 422 million, while the annual number of deaths is 1.6 million. And it is estimated that 700 million people will suffer from this challenging disease by 2045.
The diabetes market is expected to reach $ 2.8 billion by 2026. Unsurprisingly, companies developing technologies to treat diabetes are attracting the attention of long-term investors.
In this article I analyze two diabetes companies Senseonics Holdings Inc . (SENS) and Insulet Corp. . (PODD) to see which of their stocks is a better buy right now.
Read on on StockNews
Disclaimer: Fusion Media would like to remind you that the data contained on this website is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that may arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.
